Kalytera Therapeutics Inc. Stock Price - KALTF

Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Kalytera Therapeutics Inc. KALTF Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.0046 15.65% 0.034 0.035 0.0307 0.035 0.0294 16:11:36
Bid Price Ask Price Spread Spread % News
0.021 0.036 0.015 41.67% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
11 146,534 $ 0.032017 $ 4,692 265,440 0.0248 - 0.1382
Last Trade Time Type Quantity Stock Price Currency
15:30:23 23,000 $ 0.034 USD

Kalytera Therapeutics Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 16.98M 499.34M $ 6.94M - 2.45 254.78M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
59.73k $ - 0.00% - -

more financials information »

Kalytera Therapeutics Inc. News

Latest KALTF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical KALTF Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.0290.0350.0250.0289173k0.00517.24%
1 Month0.03790.0410.0250.0343307k-0.0039-10.29%
3 Months0.030050.0470.02480.0340275k0.0039513.14%
6 Months0.065530.080.02480.0434248k-0.03153-48.12%
1 Year0.10210.13820.02480.0647267k-0.0681-66.70%
3 Years0.020.610.020.1210181k0.01470.00%
5 Years0.0020.610.00010.1208175k0.0321,600.00%

Kalytera Therapeutics Inc. Description

Kalytera Therapeutics is a clinical-stage pharmaceutical company pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on Graft versus Host Disease ("GvHD"). Kalytera is also developing a new class of proprietary cannabidiol ("CBD") therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability. Kalytera is developing innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera has filed composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.

Your Recent History
Kalytera T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.